Serine

Serine

SCHEMBL1067385

C[C@H](N)C(=O)OC(=O)[C@@H](N)[C@@H](C)O.N[C@@H](CO)C(=O)O

nearest known ligand 0.37

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 2/20 0.37
SLC1A1 P43005 4/20 0.35
SLC1A3 P43003 4/20 0.34
SLC1A2 P43004 4/20 0.34
USP2 O75604 1/20 0.34
SLCO1B1 Q9Y6L6 1/20 0.34
PDCD1LG2 Q9BQ51 1/20 0.32
CD274 Q9NZQ7 1/20 0.32
GRIK1 P39086 3/20 0.32
GRIA4 P48058 3/20 0.32
GRIK3 Q13003 3/20 0.32
GRIK5 Q16478 3/20 0.32
PTGS1 P23219 1/20 0.31
SLC7A11 Q9UPY5 1/20 0.31
LAP3 P28838 2/20 0.31
GRIA2 P42262 2/20 0.31
GRIA1 P42261 1/20 0.31
GRIK2 Q13002 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Serine SCHEMBL17603641 0.89 SLC7A5 (0.45) SLC7A5SLC1A1SLC1A3SLC1A2GRIK1
Serine SCHEMBL5698241 0.84 SLC7A5 (0.33) SLC7A5SLC1A1SLC1A3SLC1A2USP2
SCHEMBL3191865 0.84 SLC7A5 (0.33) SLC7A5
Serine SCHEMBL9716090 0.83 ALOX15 (0.46) SLC7A5SLC1A1SLC1A3SLC1A2PDCD1LG2
Threonine SCHEMBL9716069 0.80 USP2 (0.44) SLC7A5SLC1A1SLC1A3SLC1A2USP2
Threonine SCHEMBL1067383 0.80 USP2 (0.44) SLC7A5SLC1A1SLC1A3SLC1A2USP2
Threonine SCHEMBL1067389 0.80 USP2 (0.44) SLC7A5SLC1A1SLC1A3SLC1A2USP2
Threonine SCHEMBL1697282 0.80 USP2 (0.44) SLC7A5SLC1A1SLC1A3SLC1A2USP2
Threonine SCHEMBL9716088 0.80 USP2 (0.44) SLC7A5SLC1A1SLC1A3SLC1A2USP2
Serine SCHEMBL1018118 0.80 PTGS1 (0.48) SLC7A5SLC1A1SLC1A3SLC1A2GRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2453920-A2 ANTAGONISTS, USES & METHODS FOR PARTIALLY INHIBITING TNFR1 Glaxo Group Limited (GB) 2012-05-23 EP disclosed
US-20120107330-A1 ANTAGONISTS, USES & METHODS FOR PARTIALLY INHIBITING TNFR1 GLAXO GROUP LIMITED (GB) 2012-05-03 US disclosed
EP-2398827-A2 IMPROVED ANTI-TNFR1 POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS&ANTAGONISTS Glaxo Group Limited (GB) 2011-12-28 EP disclosed
US-20110301335-A1 ANTI-TNFR1 POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS & ANTAGONISTS GLAXO GROUP LIMITED (GB) 2011-12-08 US disclosed
WO-2011006914-A2 ANTAGONISTS, USES & METHODS FOR PARTIALLY INHIBITING TNFR1 GLAXO GROUP LIMITED (GB) 2011-01-20 WO disclosed
WO-2010094720-A2 IMPROVED ANTI-TNFR1 POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS & ANTAGONISTS GLAXO GROUP LIMITED (GB) 2010-08-26 WO disclosed
WO-2004039332-A2 METHODS FOR USING OSTEOCALCIN ATHERSYS, INC. (US) 2004-05-13 WO disclosed
EP-1244689-A2 CYTOKINE POLYPEPTIDES AND NUCLEIC ACIDS Maxygen, Inc. (US) 2002-10-02 EP disclosed
WO-2001040257-A2 MODIFIED IL-12 SUBUNITS AND NUCLEIC ACIDS ENCODING THEM MAXYGEN, INC. (US) 2001-06-07 WO disclosed
US-5141870-A Transforming plants with mutant fragment confers herbicide resistance E. I. DU PONT DE NEMOURS AND COMPANY (US) 1992-08-25 US disclosed